We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Technology Autonomously Detects AI Hallucinations in Digital Pathology

By LabMedica International staff writers
Posted on 19 Jun 2025

Traditional tissue staining, a fundamental tool in diagnosing diseases like cancer, involves chemical dyes to highlight microscopic features in tissue samples. More...

While effective, the process is time-consuming, destructive, and dependent on physical resources. Virtual staining—an artificial intelligence (AI)-powered approach that simulates histochemical staining from autofluorescence microscopy—offers a faster, non-destructive alternative. However, it comes with a major challenge: hallucinations, or AI-generated features that do not exist in the real tissue, which can mislead even expert pathologists. Researchers have now introduced an autonomous image quality assessment tool to detect hallucinations in virtually stained images.

Developed by a research team at the University of California, Los Angeles (UCLA, Los Angeles, CA, USA), in collaboration with pathologists from multiple institutions, the AI tool named AQuA (Autonomous Quality Assessment) is specifically built to identify image inconsistencies without needing histochemically stained ground truth data or access to the virtual staining model itself. AQuA functions by using iterative image translation cycles between autofluorescence and H&E domains. These cycles amplify minute discrepancies within the image, generating sequences that are assessed by an ensemble of neural networks. This digital “panel of judges” evaluates image quality and flags hallucinations before the images reach clinical experts. The system operates independently from the original staining model and adapts to various tissue types and staining methods, making it both scalable and broadly applicable in digital pathology.

The researchers validated AQuA using human kidney and lung biopsy samples. The findings, published in Nature Biomedical Engineering, show that the tool achieved 99.8% and 97.8% accuracy, respectively, in distinguishing high-quality from flawed virtually stained images, without relying on traditional staining images. Moreover, AQuA showed over 98% agreement with board-certified pathologists and, in certain scenarios, outperformed them, particularly in identifying deceptive hallucinations in the absence of ground truth references. The team also demonstrated AQuA’s versatility by applying it to conventionally stained slides, where it successfully detected common clinical artifacts. With AI tools becoming more integral to diagnostic workflows, quality assurance systems like AQuA are essential to ensure reliability and safety. AQuA enables rapid, accurate, and automated validation of AI-generated pathology images, paving the way for scalable and trustworthy adoption of virtual staining and digital pathology in clinical practice.

“With AQuA, we are adding a layer of trust to AI-generated images in medicine,” said UCLA Professor Aydogan Ozcan, the study’s senior author. “It acts like a digital second opinion, tirelessly checking every virtually stained tissue slide to ensure it is safe for diagnosis.”

Related Links:
UCLA


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.